GLPwatch
Effect of Renal Impairment on the Pharmacokinetics of NN9535
NCT00833716 · Completed
Last updated 2026-05-28This clinical trial studied how kidney function affects the levels of the medication NN9535 in adults with type 2 diabetes and varying degrees of kidney impairment.
Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) treatment study
Participants 62 people
Who can join Ages 18–75 · all sexes
Timeline Started 2009-02 · est. completion 2010-07
Where 3 sites · United States
What this study is testing ClinicalTrials.gov NCT00833716 ↗
Description as written by the study sponsor.
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
Treatments tested
- semaglutide also known as NN9535 Drug
10 mg/mL of semaglutide solution for s.c. injection, single dose
| Main thing measured | AUC of NN9535 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Diabetes, Diabetes Mellitus, Type 2, Renal Impairment |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00833716 ↗